Abstract
Erlotinib is an orally available, small-molecule EGF receptor tyrosine kinase inhibitor. It has shown promising activity in chemotherapy-relapsed patients with advanced non-small-cell lung cancer and is now approved in many countries. To date, there have been a number of clinical studies of erlotinib therapy demonstrating its safety as well as its efficacy. This article summarizes clinical study results in advanced non-small-cell lung cancer, so that we can comprehensively understand the toxicities expected with erlotinib in non-small-cell lung cancer patients.
| Original language | English |
|---|---|
| Pages (from-to) | 993-999 |
| Number of pages | 7 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 11 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2011 |
Keywords
- elrotinib
- non-small-cell lung cancer
- toxicity
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
